Jeena Sikho Lifecare Limited has informed the Exchange about Transcript to the Conference Call for the quarter ended 30th June, 2025
JSLL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Jeena Sikho Lifecare filed the transcript of its Q1 FY26 earnings call held on August 18, 2025. The company recently migrated to the main board of NSE and BSE on August 11, 2025. For Q1 FY26, revenue from operations stood at INR174 crore, up 74% year-on-year and 25% quarter-on-quarter, driven by 74% growth in both services and products segments. Profit after tax jumped 218% YoY to INR51 crore (EPS of INR4.13), while EBITDA rose 220% YoY to INR78.8 crore at a 45% margin. Operational bed capacity expanded to 2,180 (total 2,570 beds), with reach across 100+ cities and 23 states. Management guided for FY26 revenue of INR700 crore with a sustainable 20-25% PAT margin, and outlined plans to scale beds to 7,000-10,000 in 3-5 years, launch 15 OTC products targeting INR500 crore turnover in 1.5-2 years, and onboard Grant Thornton as statutory auditor from Q2.
Strong Q1 print and main-board migration are positive signals for shareholders. However, management indicated the 29-30% Q1 PAT margin should be treated as exceptional and guided to a more sustainable 20-25%, which may temper near-term earnings expectations despite robust revenue growth.